Shanghai Haohai Biological Technology Co., Ltd. provided group earnings guidance for the year ended 31 December 2021. For the year, the Group is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB 350,000,000.00 to RMB 380,000,000.00, representing an increase of approximately RMB 119,929,900.00 to RMB 149,929,900.00, or approximately 52.13% to 65.17%, as compared to that in 2020 (2020: audited net profit attributable to shareholders of the Company of RMB 230,070,084.81). The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB 324,000,000.00 to RMB 354,000,000.00, representing an increase of approximately RMB 117,573,600.00 to RMB 147,573,600.00, or approximately 56.96% to 71.49%, as compared to that in 2020 (2020: audited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB 206,426,385.76).
Shanghai Haohai Biological Technology Co., Ltd.
Equities
6826
CNE100001W69
Medical Equipment, Supplies & Distribution
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
40.5 HKD | +0.87% | +8.29% | +0.50% |
Mar. 11 | Shanghai Haohai's 2023 Profit Rises on Higher Revenue; Shares Rise 5% | MT |
Mar. 08 | Shanghai Haohai Biological Technology Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.50% | 1.92B | |
-2.92% | 185B | |
-3.80% | 107B | |
-5.48% | 67.55B | |
+11.22% | 54.6B | |
+16.74% | 47.42B | |
+2.24% | 42.24B | |
+4.56% | 28.24B | |
+1.64% | 26.42B | |
+11.47% | 25.66B |
- Stock Market
- Equities
- 6826 Stock
- News Shanghai Haohai Biological Technology Co., Ltd.
- Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2021